Physician profile
Komal Rastogi
NPI 1063774669
$9,168.23
in general payments reported to CMS, 2019-2025
62 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,775 · 2020: $537 · 2021: $871 · 2022: $815 · 2023: $1,935 · 2024: $1,213 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,658 · Travel and Lodging: $299 · Consulting Fee: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,658.44 |
| Travel and Lodging | $299.32 |
| Consulting Fee | $212.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,626.64 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $1,078.71 | 2022-2025 | Percept Pc Brainsense |
| Abbvie INC. | $694.02 | 2022-2025 | |
| Argenx US, INC. | $580.88 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $529.68 | 2019-2025 | Mavenclad |
| Ucb, INC. | $461.69 | 2019-2025 | Rystiggo, Briviact, Zilbrysq |
| Tg Therapeutics, INC. | $275.67 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $265.75 | 2019-2025 | Nuplazid, Daybue |
| Genzyme Corporation | $228.23 | 2019-2023 | |
| Lundbeck LLC | $221.14 | 2022-2025 | Vyepti, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $217.54 | 2023-2024 | Hyqvia, Gammagard |
| Immedica Pharma US, INC. | $212.50 | 2023 | |
| Celgene Corporation | $212.10 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $184.61 | 2021-2025 | Ultomiris |
| Genentech USA, INC. | $154.41 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Rastogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.